Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: A subgroup analysis of J-ROCKET AF

Journal of Stroke and Cerebrovascular Diseases

Volumn 22, Issue 8, 2013, Pages 1317-1325

  Tanahashi, Norio ^a   Hori, Masatsugu ^b   Matsumoto, Masayasu ^c   Momomura, Shin Ichi ^d   Uchiyama, Shinichiro ^e   Goto, Shinya ^f   Izumi, Tohru ^g   Koretsune, Yukihiro ^h   Kajikawa, Mariko ⁱ   Kato, Masaharu ⁱ   Ueda, Hitoshi ⁱ   Iwamoto, Kazuya ⁱ   Tajiri, Masahiro ⁱ  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h OSAKA NATIONAL HOSPITAL   (Japan)

ⁱ BAYER YAKUHIN LTD   (Japan)

Author keywords

Ischemic stroke; J ROCKET AF; rivaroxaban; secondary prevention warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; BACKACHE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONTUSION; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; EPISTAXIS; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SECONDARY PREVENTION; SUBCUTANEOUS HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; PROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MORPHOLINES; PROSPECTIVE STUDIES; SECONDARY PREVENTION; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84878085924     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2012.12.010     Document Type: Article

References (13)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: The Framingham Study Stroke 22 1991 983 988
2. W.B. Kannel, and E.J. Benjamin Status of the epidemiology of atrial fibrillation Med Clin North Am 92 2008 17 40
3. Stroke Risk in Atrial Fibrillation Working Group Independent predictors of stroke in patients with atrial fibrillation: A systematic review Neurology 69 2007 546 554
4. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
5. Japanese Circulation Society Joint Working Group Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version Circ J 74 2010 2479 2500
6. V. Fuster, L.E. Rydén, and D.S. Cannom ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 2006 e257 e354
7. D. Kubitza, M. Becka, and G. Wensing Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 2005 873 880
8. D. Kubitza, M. Becka, and A. Roth Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects Curr Med Res Opin 24 2008 2757 2765
9. E. Perzborn, J. Strassburger, and A. Wilmen In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor J Thromb Haemost 3 2005 514 521
10. M. Hori, M. Matsumoto, and N. Tanahashi Rivaroxaban versus warfarin in Japanese patients with atrial fibrillation Circ J 76 2012 2104 2111
11. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
12. G.J. Hankey, M.R. Patel, and S.R. Stevens Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of ROCKET AF Lancet Neurol 11 2012 315 322
13. N. Mackman The role of tissue factor and factor VIIa in hemostasis Anesth Analg 108 2009 1447 1452